{
    "abstract": "Haemophilus influenzae type b (Hib) conjugate vaccines have drastically reduced disease incidence worldwide. Protection against Hib infection has relied on the serum bactericidal activity (SBA) of antibodies to the Hib capsular polysaccharide (polyribosylribitol phosphate). However, licensure usually relies on measuring induction of antibodies to PRP as a surrogate for SBA. In a phase III clinical trial we compared a PRP-conjugate vaccine using the nontoxic diphtheria toxin mutant, CRM197, as carrier protein with the licensed tetanus toxoid conjugate when administered subcutaneously as a three dose primary series in Japanese infants. As an addition to the phase III study, we have now evaluated SBA and show PRP-CRM197 induces higher levels of SBA than PRP-T four weeks after the primary series, with a statistically significant correlation with anti-PRP titers. This data confirms the superior immunogenicity of PRP-CRM197 compared with PRP-T assessed as SBA following a three-dose primary series by subcutaneous administration. Clinical trial registry: Registered on ClinicalTrials.gov (NCT01379846).",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Naruhiko",
                    "initial": "N.",
                    "last": "Ishiwada"
                },
                {
                    "first": "Haruka",
                    "initial": "H.",
                    "last": "Hishiki"
                },
                {
                    "first": "Koo",
                    "initial": "K.",
                    "last": "Nagasawa"
                },
                {
                    "first": "Sachiko",
                    "initial": "S.",
                    "last": "Naito"
                },
                {
                    "first": "Yasunori",
                    "initial": "Y.",
                    "last": "Sato"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Chang"
                },
                {
                    "first": "Yuko",
                    "initial": "Y.",
                    "last": "Sasaki"
                },
                {
                    "first": "Kouji",
                    "initial": "K.",
                    "last": "Kimura"
                },
                {
                    "first": "Makoto",
                    "initial": "M.",
                    "last": "Ohnishi"
                },
                {
                    "first": "Keigo",
                    "initial": "K.",
                    "last": "Shibayama"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.07.100",
            "firstpage": "5425",
            "issn": "0264410X",
            "lastpage": "5431",
            "pmid": "25131741",
            "pub_year": 2014,
            "title": "The incidence of pediatric invasive Haemophilus influenzae and pneumococcal disease in Chiba prefecture, Japan before and after the introduction of conjugate vaccines",
            "volume": "32"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Takehiro",
                    "initial": "T.",
                    "last": "Togashi"
                },
                {
                    "first": "Nodoka",
                    "initial": "N.",
                    "last": "Mitsuya"
                },
                {
                    "first": "Osamu",
                    "initial": "O.",
                    "last": "Kogawara"
                },
                {
                    "first": "Shuji",
                    "initial": "S.",
                    "last": "Sumino"
                },
                {
                    "first": "Yohei",
                    "initial": "Y.",
                    "last": "Takanami"
                },
                {
                    "first": "Kayoko",
                    "initial": "K.",
                    "last": "Sugizaki"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.05.050",
            "firstpage": "4635",
            "issn": "0264410X",
            "lastpage": "4641",
            "pmid": "27265451",
            "pub_year": 2016,
            "title": "Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study",
            "volume": "34"
        },
        "b0015": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Kayhty"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Peltola"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Karanko"
                },
                {
                    "first": "P. H.",
                    "initial": "P.H.",
                    "last": "Makela"
                }
            ],
            "doi": "10.1093/infdis/147.6.1100",
            "firstpage": "1100",
            "issn": "00221899",
            "pmid": "6602191",
            "pub_year": 1983,
            "title": "The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b",
            "volume": "147"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Eli B.",
                    "initial": "E.B.",
                    "last": "Nix"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Hawdon"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Gravelle"
                },
                {
                    "first": "Birubi",
                    "initial": "B.",
                    "last": "Biman"
                },
                {
                    "first": "Malcolm",
                    "initial": "M.",
                    "last": "Brigden"
                },
                {
                    "first": "Saleem",
                    "initial": "S.",
                    "last": "Malik"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "McCready"
                },
                {
                    "first": "Garry",
                    "initial": "G.",
                    "last": "Ferroni"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Ulanova"
                }
            ],
            "doi": "10.1128/CVI.05675-11",
            "firstpage": "766",
            "issn": "15566811",
            "lastpage": "771",
            "pmid": "22398246",
            "pub_year": 2012,
            "title": "Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era",
            "volume": "19"
        },
        "b0025": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ulanova"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Hahn-Zoric"
                },
                {
                    "first": "Y. L.",
                    "initial": "Y.L.",
                    "last": "Lau"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Lucas"
                },
                {
                    "first": "L. \u00c5",
                    "initial": "L.A.",
                    "last": "Hanson"
                }
            ],
            "doi": "10.1046/j.1365-2249.1996.d01-788.x",
            "firstpage": "422",
            "issn": "00099104",
            "lastpage": "428",
            "pmid": "8809129",
            "pub_year": 1996,
            "title": "Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies",
            "volume": "105"
        },
        "b0030": null,
        "b0035": {
            "authors": [
                {
                    "first": "Kelly",
                    "initial": "K.",
                    "last": "Townsend"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.08.010",
            "firstpage": "5650",
            "issn": "0264410X",
            "lastpage": "5656",
            "pmid": "25138290",
            "pub_year": 2014,
            "title": "Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection",
            "volume": "32"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Amir"
                },
                {
                    "first": "Xiayuan",
                    "initial": "X.",
                    "last": "Liang"
                },
                {
                    "first": "Dan M.",
                    "initial": "D.M.",
                    "last": "Granoff"
                }
            ],
            "doi": "10.1203/00006450-199004000-00008",
            "firstpage": "358",
            "issn": "00313998",
            "lastpage": "364",
            "pmid": "2342828",
            "pub_year": 1990,
            "title": "Variability in the functional activity of vaccine-induced antibody to haemophilus influenza type b",
            "volume": "27"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "Willie",
                    "initial": "W.",
                    "last": "Spear"
                },
                {
                    "first": "Nekeidra",
                    "initial": "N.",
                    "last": "Brown"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Holder"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Hennessy"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Gomez De Leon"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                }
            ],
            "doi": "10.1128/CDLI.11.1.89-93.2004",
            "firstpage": "89",
            "issn": "1071412X",
            "lastpage": "93",
            "pmid": "14715550",
            "pub_year": 2004,
            "title": "Measurement of Serum Bactericidal Activity Specific for Haemophilus influenzae Type b by Using a Chromogenic and Fluorescent Metabolic Indicator",
            "volume": "11"
        },
        "b0050": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Romero-Steiner"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Fernandez"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Biltoft"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Wohl"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Sanchez"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Feris"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Balter"
                },
                {
                    "first": "O. S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                }
            ],
            "doi": "10.1128/CDLI.8.6.1115-1119.2001",
            "firstpage": "1115",
            "issn": "1071412X",
            "lastpage": "1119",
            "pmid": "11687449",
            "pub_year": 2001,
            "title": "Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate)",
            "volume": "8"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Dagan"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Hallander"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1586/erv.11.142",
            "firstpage": "1621",
            "issn": "14760584",
            "lastpage": "1631",
            "pmid": "22043960",
            "pub_year": 2011,
            "title": "Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules",
            "volume": "10"
        },
        "b0060": {
            "authors": [
                {
                    "first": "G\u00fcler",
                    "initial": "G.",
                    "last": "Kanra"
                },
                {
                    "first": "Simonetta",
                    "initial": "S.",
                    "last": "Viviani"
                },
                {
                    "first": "Kadriye",
                    "initial": "K.",
                    "last": "Yurdak\u00f6k"
                },
                {
                    "first": "Elif",
                    "initial": "E.",
                    "last": "\u00d6zmert"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "Song\u00fcl",
                    "initial": "S.",
                    "last": "Yal\u00e7in"
                },
                {
                    "first": "Okan",
                    "initial": "O.",
                    "last": "Demiralp"
                },
                {
                    "first": "Nihan",
                    "initial": "N.",
                    "last": "Bilgili"
                },
                {
                    "first": "Ates",
                    "initial": "A.",
                    "last": "Kara"
                },
                {
                    "first": "Ali B\u00fclent",
                    "initial": "A.B.",
                    "last": "Cengiz"
                },
                {
                    "first": "Belgin",
                    "initial": "B.",
                    "last": "Mutlu"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Baldini"
                },
                {
                    "first": "Elisa",
                    "initial": "E.",
                    "last": "Marchetti"
                },
                {
                    "first": "Audino",
                    "initial": "A.",
                    "last": "Podda"
                }
            ],
            "doi": "10.1046/j.1442-200X.2003.01706.x",
            "firstpage": "314",
            "issn": "13288067",
            "lastpage": "318",
            "pmid": "12828588",
            "pub_year": 2003,
            "title": "Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine",
            "volume": "45"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "Bradley"
                },
                {
                    "first": "Pamela",
                    "initial": "P.",
                    "last": "Palmer"
                }
            ],
            "doi": "10.1016/S0022-3476(05)80424-X",
            "firstpage": "184",
            "issn": "00223476",
            "lastpage": "189",
            "pmid": "1735812",
            "pub_year": 1992,
            "title": "Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines",
            "volume": "120"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Ewa",
                    "initial": "E.",
                    "last": "Oleszycka"
                },
                {
                    "first": "Ed C.",
                    "initial": "E.C.",
                    "last": "Lavelle"
                }
            ],
            "doi": "10.1016/j.coi.2013.12.007",
            "firstpage": "1",
            "issn": "09527915",
            "lastpage": "5",
            "pmid": "24463269",
            "pub_year": 2014,
            "title": "Immunomodulatory properties of the vaccine adjuvant alum",
            "volume": "28"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Peng",
                    "initial": "P.",
                    "last": "He"
                },
                {
                    "first": "Yening",
                    "initial": "Y.",
                    "last": "Zou"
                },
                {
                    "first": "Zhongyu",
                    "initial": "Z.",
                    "last": "Hu"
                }
            ],
            "doi": "10.1080/21645515.2014.1004026",
            "firstpage": "477",
            "issn": "21645515",
            "lastpage": "488",
            "pmid": "25692535",
            "pub_year": 2015,
            "title": "Advances in aluminum hydroxide-based adjuvant research and its mechanism",
            "volume": "11"
        },
        "b0080": {
            "authors": [
                {
                    "first": "L. R.",
                    "initial": "L.R.",
                    "last": "Bulkow"
                },
                {
                    "first": "R. B.",
                    "initial": "R.B.",
                    "last": "Wainwright"
                },
                {
                    "first": "G. W.",
                    "initial": "G.W.",
                    "last": "Letson"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Chang"
                },
                {
                    "first": "J. I.",
                    "initial": "J.I.",
                    "last": "Ward"
                }
            ],
            "firstpage": "484",
            "issn": "08913668",
            "lastpage": "492",
            "pmid": "8345981",
            "pub_year": 1993,
            "title": "Comparative immunogenicity of four haemophilus influenzae type b conjugate vaccines in alaska native infants",
            "volume": "12"
        }
    },
    "body_text": [
        {
            "endOffset": 17870,
            "parents": [],
            "secId": "s0040",
            "sentence": "Nevertheless, PRP-T drastically decreases the numbers of severe cases of Hib infection in children by providing protective immunity against Hib infection under the current national immunization program in Japan.",
            "startOffset": 17659,
            "title": "Discussion"
        },
        {
            "endOffset": 15415,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15414,
                    "startOffset": 15411
                }
            },
            "secId": "s0040",
            "sentence": "Both PRP-CRM197 and PRP-T vaccines induced marked increases in SBA titers after the third immunization compared with pre-vaccination levels as well as anti-PRP IgG concentrations [2].",
            "startOffset": 15232,
            "title": "Discussion"
        },
        {
            "endOffset": 13454,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13453,
                    "startOffset": 13450
                }
            },
            "secId": "s0035",
            "sentence": "A total of 415 children were immunized with three doses of Hib vaccine (either PRP-CRM197 or PRP-T) given as a primary series and a booster vaccination [2].",
            "startOffset": 13298,
            "title": "Results"
        },
        {
            "endOffset": 9526,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "An Institutional Review Board approved the study protocol, which was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Standards and applicable local regulations.",
            "startOffset": 9330,
            "title": "Study design"
        },
        {
            "endOffset": 18619,
            "parents": [],
            "secId": "s0040",
            "sentence": "One limitation of our study is that even though the Hib vaccines were administered in three doses as a primary series and that the booster vaccination was administered 1 year after the primary series, we only measured SBA titer after the third immunization in the primary series.",
            "startOffset": 18340,
            "title": "Discussion"
        },
        {
            "endOffset": 15564,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 15563,
                    "startOffset": 15560
                }
            },
            "secId": "s0040",
            "sentence": "In our study, SBA GMTs after the third immunization with either PRP-CRM197 or PRP-T were above a seroprotective threshold, as recently reported [7].",
            "startOffset": 15416,
            "title": "Discussion"
        },
        {
            "endOffset": 10939,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Anti-PRP IgG was measured by using VaccZyme\u2122 Human Anti-Haemophilus influenzae type b Enzyme Immunoassay Kit (The Binding Site Group, UK), according to the manufacturer\u2019s instructions.",
            "startOffset": 10755,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 18340,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 18339,
                    "startOffset": 18336
                }
            },
            "secId": "s0040",
            "sentence": "Although the advantage of PRP-CRM197 over PRP-T may be subtle, PRP-CRM197-administered subjects who had not yet completed the booster vaccination phase showed higher geometric mean concentration for anti-PRP antibody (after the third vaccination and before the booster vaccination) and SBA (after the third vaccination), suggesting that PRP-CRM197 administration can decrease the incidence of vaccine failures between the primary and booster phases of immunization [2].",
            "startOffset": 17871,
            "title": "Discussion"
        },
        {
            "endOffset": 19239,
            "parents": [],
            "secId": "s0040",
            "sentence": "Therefore, further studies would be required to confirm this.",
            "startOffset": 19178,
            "title": "Discussion"
        },
        {
            "endOffset": 10348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Both vaccines were administered subcutaneously to children aged between 3 and 6 months at the time of the first dose in a three-dose primary series (4 weeks intervals), with a booster vaccination administered at approximately 1 year after completion of the primary series.",
            "startOffset": 10076,
            "title": "Vaccines and vaccination"
        },
        {
            "endOffset": 8025,
            "parents": [],
            "secId": "s0005",
            "sentence": "We have previously reported on a phase III clinical trial comparing the immunogenicity of Vaxem\u2122 Hib (PRP conjugated with a nontoxic diphtheria toxin mutant, CRM197, containing aluminum phosphate adjuvant [PRP-CRM197]) with PRP-T.",
            "startOffset": 7795,
            "title": "Introduction"
        },
        {
            "endOffset": 17212,
            "parents": [],
            "secId": "s0040",
            "sentence": "However, there were non-responders (SBA < 16) in each group.",
            "startOffset": 17152,
            "title": "Discussion"
        },
        {
            "endOffset": 13290,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Statistical analyses were performed using SAS Ver.9.2 (SAS Institute Inc.).",
            "startOffset": 13215,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 12231,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "SBA titers were expressed as the reciprocal of the serum dilution that resulted in 50% killing of the initial inoculum compared with that achieved with the fluorescence of a known concentration (in colony-forming units, CFU) of bacterial controls.",
            "startOffset": 11984,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 13766,
            "parents": [],
            "secId": "s0035",
            "sentence": "Proportions of subjects with titers above the threshold for long-term seroprotection were 99.3% and 95.6% in the PRP-CRM197 and PRP-T groups, respectively.",
            "startOffset": 13611,
            "title": "Results"
        },
        {
            "endOffset": 17029,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 17028,
                    "startOffset": 17024
                }
            },
            "secId": "s0040",
            "sentence": "A previous study found that aluminum-containing adjuvants increased the response to PRP-CRM197, but the effect on PRP-T has not been similarly evaluated [12].",
            "startOffset": 16871,
            "title": "Discussion"
        },
        {
            "endOffset": 8874,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 8736,
                    "startOffset": 8731
                },
                "b0025": {
                    "endOffset": 8736,
                    "startOffset": 8731
                },
                "b0030": {
                    "endOffset": 8873,
                    "startOffset": 8870
                }
            },
            "secId": "s0005",
            "sentence": "Several publications have reported that cross-reactive antigens may induce non-functional antibody against Hib [4,5], and vaccine failure was reported to occur in one infant with sufficient anti-PRP antibody (\u22651.0 \u00b5g/ml) but low SBA titer (SBA = 16) [6].",
            "startOffset": 8620,
            "title": "Introduction"
        },
        {
            "endOffset": 14549,
            "parents": [],
            "secId": "s0035",
            "sentence": "These subjects may explain the cases of vaccine failure or breakthrough infection of Hib that have been described historically to occur following vaccination.",
            "startOffset": 14391,
            "title": "Results"
        },
        {
            "endOffset": 11155,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0040": {
                    "endOffset": 11154,
                    "startOffset": 11151
                }
            },
            "secId": "s0025",
            "sentence": "In this additional analysis, SBA was measured in the samples taken before and after the primary series at Shin Nippon Biomedical Laboratories, Ltd following a previously reported method with minor modifications [8].",
            "startOffset": 10940,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 17151,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 17075,
                    "startOffset": 17072
                }
            },
            "secId": "s0040",
            "sentence": "In this report as well as previous reports [7], the specific antibody titer against Hib-PRP was correlated with SBA titer.",
            "startOffset": 17029,
            "title": "Discussion"
        },
        {
            "endOffset": 15221,
            "parents": [],
            "secId": "s0035",
            "sentence": "This analysis indicated that immunization with PRP-CRM197 resulted in significantly fewer non-responders than those who received PRP-T with antibody levels exceeding the short term-seroprotective threshold (%responders: 97.8% [95% CI, 96.0\u201399.54] vs. 87.9% [95% CI, 82.3\u201393.4]) and fewer non-responders with antibody levels exceeding the long term-seroprotective threshold (%responders: 98.5% [95% CI, 96.2\u201399.6] vs. 91.3% [95% CI, 86.3\u201396.2]).",
            "startOffset": 14777,
            "title": "Results"
        },
        {
            "endOffset": 12731,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The SBA titer was set as an exploratory endpoint.",
            "startOffset": 12682,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 14390,
            "parents": [],
            "secId": "s0035",
            "sentence": "Although there was a moderate correlation between anti-PRP antibody levels and SBA titers for PRP-CRM197 (n = 263, r = 0.3543, p < 0.0001) and PRP-T (n = 115, r = 0.3349, p = 0.0003) (Fig. 1.B), a few subjects with \u22651.0 \u00b5g/ml (long-term) in both groups who had an SBA titer <16.",
            "startOffset": 14112,
            "title": "Results"
        },
        {
            "endOffset": 16870,
            "parents": [],
            "secId": "s0040",
            "sentence": "However, the effect of aluminum-containing adjuvants in Hib vaccines on the SBA titer under clinical trial conditions has not been studied, and we cannot distinguish between any potential effects of aluminum in our study as the two vaccines use different carrier proteins.",
            "startOffset": 16598,
            "title": "Discussion"
        },
        {
            "endOffset": 14776,
            "parents": [],
            "secId": "s0035",
            "sentence": "Consequently, subjects with anti-PRP IgG antibody titers \u22650.15 \u00b5g/ml (short-term) or \u22651.0 \u00b5g/ml (long-term) were categorized as non-responders (SBA < 16) or responders (SBA \u2265 16), and their numbers were compared in each group.",
            "startOffset": 14550,
            "title": "Results"
        },
        {
            "endOffset": 16398,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 16397,
                    "startOffset": 16394
                },
                "b0045": {
                    "endOffset": 16067,
                    "startOffset": 16064
                },
                "b0050": {
                    "endOffset": 16176,
                    "startOffset": 16172
                }
            },
            "secId": "s0040",
            "sentence": "Carrier proteins play an important role in provoking a T cell-dependent immune response from T cell-independent antigens such as bacterial capsular polysaccharides [9], while a previous report indicated that PRP-CRM197 and PRP-T elicited similarly strong immune responses [10] as well as our previous report which indicated no interference by carrier proteins between PRP-CRM197, or PRP-T and DTaP concomitant administration in terms of their immunogenicity (the amount of specific antibodies) [2].",
            "startOffset": 15900,
            "title": "Discussion"
        },
        {
            "endOffset": 8286,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 8285,
                    "startOffset": 8282
                }
            },
            "secId": "s0005",
            "sentence": "Since no significant differences in terms of Hib PRP-specific IgG antibody titers were shown between PRP-CRM197 and PRP-T after a primary series of vaccinations in Japanese children, both vaccines were expected to be equally effective in children in Japan [2].",
            "startOffset": 8026,
            "title": "Introduction"
        },
        {
            "endOffset": 8619,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 8618,
                    "startOffset": 8615
                }
            },
            "secId": "s0005",
            "sentence": "The long-term seroprotection rate was reported to correspond to serum bactericidal activity (SBA) of 8 [3].",
            "startOffset": 8512,
            "title": "Introduction"
        },
        {
            "endOffset": 7794,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 7793,
                    "startOffset": 7790
                }
            },
            "secId": "s0005",
            "sentence": "The number of pediatric cases of invasive Hib infection in Japan has decreased due to the introduction of a Hib conjugate vaccine (ActHIB\u00ae) consisting of PRP conjugated with tetanus toxoid (PRP-T) [1].",
            "startOffset": 7593,
            "title": "Introduction"
        },
        {
            "endOffset": 8511,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 8510,
                    "startOffset": 8507
                }
            },
            "secId": "s0005",
            "sentence": "Recognized measures of Hib vaccine-induced protective immunity against Hib infection are anti-PRP antibody concentrations associated with short-term seroprotection (\u22650.15 \u00b5g/ml) and long-term seroprotection (\u22651.0 \u00b5g/ml) [3].",
            "startOffset": 8287,
            "title": "Introduction"
        },
        {
            "endOffset": 19410,
            "parents": [],
            "secId": "s0040",
            "sentence": "Our data do confirm that either of the two tested Hib conjugates can be used to provide high levels of immune protection against Hib assessed as SBA to Japanese children.",
            "startOffset": 19240,
            "title": "Discussion"
        },
        {
            "endOffset": 14009,
            "parents": [],
            "secId": "s0035",
            "sentence": "Post-immunization geometric mean SBA titers were 201.7 for PRP-CRM197, and 69.9 for PRP-T (Table 1).",
            "startOffset": 13909,
            "title": "Results"
        },
        {
            "endOffset": 15782,
            "parents": [],
            "secId": "s0040",
            "sentence": "Further, the higher SBA titers achieved with following PRP-CRM197 immunization suggest that is why this vaccine has a superior effect on short-term and long-term seroprotection rates, compared with PRP-T immunization.",
            "startOffset": 15565,
            "title": "Discussion"
        },
        {
            "endOffset": 16597,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 16596,
                    "startOffset": 16592
                }
            },
            "secId": "s0040",
            "sentence": "It is well known that adjuvants stimulate and modify immune responses to antigens [11].",
            "startOffset": 16510,
            "title": "Discussion"
        },
        {
            "endOffset": 9329,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 9328,
                    "startOffset": 9325
                }
            },
            "secId": "s0015",
            "sentence": "This phase 3, randomized observer-blind multi center, parallel-group study conducted in Japan was previously reported in detail [2].",
            "startOffset": 9197,
            "title": "Study design"
        },
        {
            "endOffset": 10075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The Hib vaccines were VAXEM\u2122 Hib, consisting of PRP conjugated with a nontoxic diphtheria toxin mutant, CRM197, containing 0.3 mg of aluminum phosphate adjuvant [Novartis Vaccine and Diagnostics, now a GSK company, and licensed by Takeda Pharmaceutical Company Limited for use in Japan] and ActHIB\u00ae, consisting of PRP conjugated to tetanus toxoid (Sanofi Pasteur S.A., Lyon, France).",
            "startOffset": 9692,
            "title": "Vaccines and vaccination"
        },
        {
            "endOffset": 19177,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 19176,
                    "startOffset": 19172
                }
            },
            "secId": "s0040",
            "sentence": "The presence of aluminum phosphate adjuvant in PRP-CRM197 may account for this difference, however, the different carrier proteins on PRP might also be the reason as observed previously [16].",
            "startOffset": 18986,
            "title": "Discussion"
        },
        {
            "endOffset": 13908,
            "parents": [],
            "secId": "s0035",
            "sentence": "Using the same sera we found a significantly higher SBA titer in the PRP-CRM197 group than in the PRP-T group (GMR, 2.88 (PRP-CRM197/PRP-T)).",
            "startOffset": 13767,
            "title": "Results"
        },
        {
            "endOffset": 14111,
            "parents": [],
            "secId": "s0035",
            "sentence": "This difference is evident as shown in reverse cumulative distribution plot for SBA titer (Fig. 1.A).",
            "startOffset": 14010,
            "title": "Results"
        },
        {
            "endOffset": 17658,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 17554,
                    "startOffset": 17550
                },
                "b0070": {
                    "endOffset": 17597,
                    "startOffset": 17590
                },
                "b0075": {
                    "endOffset": 17597,
                    "startOffset": 17590
                }
            },
            "secId": "s0040",
            "sentence": "It might be expected that the aluminum phosphate adjuvant in PRP-CRM197 may further stimulate the production of high levels of circulating antibodies, the formation of long-lived CD27+ IgG+ memory cell pools [13] or other newly proposed mechanisms [14,15], thereby increasing SBA in PRP-CRM197-administered children.",
            "startOffset": 17342,
            "title": "Discussion"
        },
        {
            "endOffset": 10754,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Four blood samples were drawn; before the first vaccination, and 4 weeks after the third vaccination, and before and 4 weeks after the booster vaccination.",
            "startOffset": 10599,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 11983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "H. influenzae (103 bacteria/well), followed by 25 \u00b5l of rabbit complement (Pel-Freez) and 25 \u00b5l of alamar Blue solution (16% alamar Blue [Trek Diagnostics], 64% dilution buffer, and 2% BHI medium), were added to each of the microtiter plate wells before incubation at 37 \u00b0C for 6 h in a 5% CO2 atmosphere and then fluorescence measurement (Ex/Em = 530/590 nm).",
            "startOffset": 11623,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 15899,
            "parents": [],
            "secId": "s0040",
            "sentence": "These vaccines differ in the carrier proteins conjugated with Hib PRP and in containing aluminum phosphate adjuvant.",
            "startOffset": 15783,
            "title": "Discussion"
        },
        {
            "endOffset": 13610,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 13482,
                    "startOffset": 13479
                }
            },
            "secId": "s0035",
            "sentence": "As described previously [4], the level of anti-PRP specific IgG was increased after the primary series with PRP-CRM197 (18.0 \u00b5g/ml), or PRP-T (8.67 \u00b5g/ml).",
            "startOffset": 13455,
            "title": "Results"
        },
        {
            "endOffset": 8982,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 8981,
                    "startOffset": 8976
                },
                "b0040": {
                    "endOffset": 8981,
                    "startOffset": 8976
                },
                "b0045": {
                    "endOffset": 8981,
                    "startOffset": 8976
                }
            },
            "secId": "s0005",
            "sentence": "It has been suggested that SBA is the more reliable predictor of successful immunization against Hib [7\u20139].",
            "startOffset": 8875,
            "title": "Introduction"
        },
        {
            "endOffset": 17341,
            "parents": [],
            "secId": "s0040",
            "sentence": "The number of non-responders was larger in the PRP-T group, and PRP-CRM197 was more immunogenic than PRP-T when assessed as SBA.",
            "startOffset": 17213,
            "title": "Discussion"
        },
        {
            "endOffset": 9603,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Informed consent was obtained from all parents or guardians of the children.",
            "startOffset": 9527,
            "title": "Study design"
        },
        {
            "endOffset": 9160,
            "parents": [],
            "secId": "s0005",
            "sentence": "To reinforce the conclusions of our clinical trial mentioned above using PRP antibody titers, we compared SBA titers between PRP-T and PRP-CRM197 in samples from the same study.",
            "startOffset": 8983,
            "title": "Introduction"
        },
        {
            "endOffset": 11622,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Heat-inactivated serum samples were added to wells of microtiter plates and serially diluted twofold starting at 1:8 in dilution buffer (Hanks buffer with Ca2+ and Mg2+, supplemented with 2% BHI medium, 10 \u00b5g/ml NAD and 10 \u00b5g/ml hemin).",
            "startOffset": 11386,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 13214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In addition, the correlation between anti-PRP IgG antibody concentration and SBA titers above the lower limit (16) was analyzed for all subjects in an exploratory analysis that was not prespecified in the statistical analysis plan.",
            "startOffset": 12983,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 10570,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "DTaP vaccine containing 0.1 mg of aluminum hydroxide adjuvant (Adsorbed Diphtheria-Purified Pertussis-Tetanus Combined Vaccine Kit TAKEDA) was administered concomitantly by subcutaneous injection in the contralateral arm.",
            "startOffset": 10349,
            "title": "Vaccines and vaccination"
        },
        {
            "endOffset": 18985,
            "parents": [],
            "secId": "s0040",
            "sentence": "In conclusion, our study confirms that PRP-CRM197 is more immunogenic than PRP-T, and stimulate a higher level of anti-PRP specific antibodies and a higher SBA titer after the primary series.",
            "startOffset": 18794,
            "title": "Discussion"
        },
        {
            "endOffset": 12982,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "With regard to the anti-PRP antibody response and SBA, the geometric mean titer (GMT) and two-sided 95% confidence interval (95% CI) were calculated for each group, and the geometric mean ratio (GMR, PRP-CRM197/PRP-T) and 95% CI were also calculated.",
            "startOffset": 12732,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 12681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 12680,
                    "startOffset": 12677
                }
            },
            "secId": "s0030",
            "sentence": "The study was designed to test the non-inferiority of PRP-CRM197 vaccine to PRP-T vaccine in terms of anti-PRP antibody response measured by seroprotection rate (titer \u22651.0 \u03bcg/mL) at 4 weeks after the third dose in the primary series (primary endpoint) [2].",
            "startOffset": 12424,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 11385,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Briefly, H. influenzae GB3291 was grown overnight in brain heart infusion (BHI) medium supplemented with NAD (nicotinamide adenine dinucleotide) and hemin at final concentrations of 10 \u00b5g/ml each, then stored at \u221280 \u00b0C until use.",
            "startOffset": 11156,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 16509,
            "parents": [],
            "secId": "s0040",
            "sentence": "Therefore, we could consider whether the use of aluminum phosphate adjuvant could account for this difference.",
            "startOffset": 16399,
            "title": "Discussion"
        },
        {
            "endOffset": 12401,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "An SBA titer less than the detection limit (<16) was considered to be 16, and only correlations between SBA titer \u226516 and anti-PRP antibody concentration were evaluated.",
            "startOffset": 12232,
            "title": "Immunogenicity measurement"
        },
        {
            "endOffset": 9665,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was registered at ClinicalTrials.gov (NCT01379846).",
            "startOffset": 9604,
            "title": "Study design"
        },
        {
            "endOffset": 18794,
            "parents": [],
            "secId": "s0040",
            "sentence": "The primary series induces immune memory, but we did not study SBA responses after a booster dose so cannot confirm an effect of aluminum of this part of the immune response.",
            "startOffset": 18620,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X18301853",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "akeda@biken.osaka-u.ac.jp",
                "first": "Yukihiro",
                "initial": "Y.",
                "last": "Akeda"
            },
            {
                "email": null,
                "first": "Yuka",
                "initial": "Y.",
                "last": "Koizumi"
            },
            {
                "email": null,
                "first": "Yohei",
                "initial": "Y.",
                "last": "Takanami"
            },
            {
                "email": null,
                "first": "Shuji",
                "initial": "S.",
                "last": "Sumino"
            },
            {
                "email": null,
                "first": "Yumi",
                "initial": "Y.",
                "last": "Hattori"
            },
            {
                "email": null,
                "first": "Kayoko",
                "initial": "K.",
                "last": "Sugizaki"
            },
            {
                "email": null,
                "first": "Nodoka",
                "initial": "N.",
                "last": "Mitsuya"
            },
            {
                "email": null,
                "first": "Kazunori",
                "initial": "K.",
                "last": "Oishi"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.02.011",
        "firstpage": "1528",
        "issn": "0264410X",
        "keywords": [
            "Aluminum phosphate adjuvant",
            "Haemophilus influenzae type b",
            "Hib conjugate vaccine",
            "Seroprotection threshold",
            "Serum bactericidal activity"
        ],
        "lastpage": "1532",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Comparison of serum bactericidal and antibody titers induced by two Haemophilus influenzae type b conjugate vaccines: A phase III randomized double-blind study"
    }
}